Health Condition 1: G998- Other specified disorders of nervous system in diseases classified elsewhere
Conditions
Interventions
Intervention1: Intranasal Dexmedetomedine 3 mcg/kg, single dose administered as a nasal spray single dose without any repetition: Intranasal Dexmedetomedine 3 mcg/kg, single dose. Compare the efficacy
Sponsors
AIIMS Bhubaneswar
Eligibility
Inclusion criteria
Inclusion criteria: Children aged 6 mo-10 yrs with Physical Status 1 and 2 (According to American Society Of Anaesthesiologist grading) requiring Magnetic Resonance Imaging
Exclusion criteria
Exclusion criteria: Patients with h/o allergy to Triclofos, Midazolam and Dexmedetomedine ââ?? Having evidence of upper respiratory tract infection/Nasal obstruction during enrollment ââ?? Epistaxis or acute rhinitis during the time of enrollment ââ?? Severe cardiorespiratory failure ââ?? Difficult airway
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the efficacy of oral Triclofos, intranasal Midazolam and Dexmedetomedine in achieving successful sedation during MRITimepoint: Paediatric State Sedation Scale assessed every 5 minutes.Typically, a PSSS of less than 4 is considered apt to tolerate diagnostic magnetic resonance imaging studies. | — |
Secondary
| Measure | Time frame |
|---|---|
| Time of onset of sedation, duration of sedation and adverse events following the use of above three drugs Timepoint: The duration of sedation will be calculated as the difference between the end and start times. All possible adverse events will be recorded. | — |
Countries
India
Contacts
Public ContactDr Shyam Chandrasekar
AIIMS Bhubaneswar
Outcome results
None listed